{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T00:38:04Z","timestamp":1792715884509,"version":"4.5.0"},"reference-count":114,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T00:00:00Z","timestamp":1789084800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JACC: CardioOncology"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.jaccao.2026.09.005","type":"journal-article","created":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T19:30:36Z","timestamp":1792524636000},"page":"463-482","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Immune Responses in Checkpoint Inhibitor\u2013Associated Cardiovascular Immune\u2013Related Adverse Events"],"prefix":"10.1016","volume":"8","author":[{"given":"Kerry L.","family":"Reynolds","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra-Chlo\u00e9","family":"Villani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zs\u00f3fia Dora","family":"Drobni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomas G.","family":"Neilan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Han","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noah S.","family":"Wagner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin M.","family":"Balko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reilly","family":"Fankhauser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javid J.","family":"Moslehi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7565-1797","authenticated-orcid":false,"given":"Nicolas L.","family":"Palaskas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristen E.","family":"Pauken","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bilal A.","family":"Siddiqui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6030-7192","authenticated-orcid":false,"given":"Steven M.","family":"Blum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel A.","family":"Zlotoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaccao.2026.09.005_bib1","first-page":"311","article-title":"Cellular pathology","volume":"1","author":"Virchow","year":"1861","journal-title":"Med Crit Psychol J"},{"key":"10.1016\/j.jaccao.2026.09.005_bib2","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/j.jaccao.2022.09.004","article-title":"Immune checkpoint inhibitor therapy in oncology: current uses and future directions: JACC: CardioOncology State-of-the-Art Review","volume":"4","author":"Tan","year":"2022","journal-title":"JACC CardioOncol"},{"key":"10.1016\/j.jaccao.2026.09.005_bib3","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1056\/NEJMra1703481","article-title":"Immune-related adverse events associated with immune checkpoint blockade","volume":"378","author":"Postow","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaccao.2026.09.005_bib4","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1001\/jamaoncol.2025.4543","article-title":"Immune checkpoint inhibitor-associated cardiovascular toxic effects: International Cardio-Oncology Society position statement","volume":"12","author":"Herrmann","year":"2026","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.jaccao.2026.09.005_bib5","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1056\/NEJMoa1609214","article-title":"Fulminant myocarditis with combination immune checkpoint blockade","volume":"375","author":"Johnson","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaccao.2026.09.005_bib6","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1111\/imr.13240","article-title":"Mediators and mechanisms of immune checkpoint inhibitor-associated myocarditis: insights from mouse and human","volume":"318","author":"Gong","year":"2023","journal-title":"Immunol Rev"},{"key":"10.1016\/j.jaccao.2026.09.005_bib7","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/j.jacc.2021.11.048","article-title":"Immune checkpoint therapies and atherosclerosis: mechanisms and clinical implications: JACC state-of-the-art review","volume":"79","author":"Vuong","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jaccao.2026.09.005_bib8","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1038\/s41568-024-00715-5","article-title":"Immune-checkpoint inhibitor-mediated myocarditis: CTLA4, PD1 and LAG3 in the heart","volume":"24","author":"Munir","year":"2024","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.jaccao.2026.09.005_bib9","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1158\/2326-6066.CIR-24-0011","article-title":"Molecular pathways and cellular subsets associated with adverse clinical outcomes in overlapping immune-related myocarditis and myositis","volume":"12","author":"Siddiqui","year":"2024","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.jaccao.2026.09.005_bib10","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.jaccao.2026.04.008","article-title":"Immune profiling identifies inflammatory signatures in immune checkpoint inhibitor-related myocarditis","volume":"8","author":"Daoudlarian","year":"2026","journal-title":"JACC CardioOncol"},{"key":"10.1016\/j.jaccao.2026.09.005_bib11","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1161\/CIRCRESAHA.124.325652","article-title":"Novel therapeutic approach targeting CXCR3 to treat immunotherapy myocarditis","volume":"136","author":"Huang","year":"2025","journal-title":"Circ Res"},{"key":"10.1016\/j.jaccao.2026.09.005_bib12","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1161\/CIRCULATIONAHA.125.076976","article-title":"CXCR6+ T cells drive immune checkpoint inhibitor myocarditis","volume":"153","author":"Munir","year":"2026","journal-title":"Circulation"},{"key":"10.1016\/j.jaccao.2026.09.005_bib13","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1161\/CIRCRESAHA.124.324260","article-title":"Visualizing immune checkpoint inhibitors derived inflammation in atherosclerosis","volume":"135","author":"Lou","year":"2024","journal-title":"Circ Res"},{"key":"10.1016\/j.jaccao.2026.09.005_bib14","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1016\/S1470-2045(18)30608-9","article-title":"Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study","volume":"19","author":"Salem","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jaccao.2026.09.005_bib15","doi-asserted-by":"crossref","first-page":"2299","DOI":"10.1161\/CIRCULATIONAHA.120.049981","article-title":"Association between immune checkpoint inhibitors with cardiovascular events and atherosclerotic plaque","volume":"142","author":"Drobni","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.jaccao.2026.09.005_bib16","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-007307","article-title":"Impact of immune checkpoint inhibitors on atherosclerosis progression in patients with lung cancer","volume":"11","author":"Drobni","year":"2023","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.jaccao.2026.09.005_bib17","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1016\/j.jaccao.2022.11.011","article-title":"Atherosclerosis with immune checkpoint inhibitor therapy: evidence, diagnosis, and management: JACC: CardioOncology state-of-the-art review","volume":"4","author":"Suero-Abreu","year":"2022","journal-title":"JACC CardioOncol"},{"key":"10.1016\/j.jaccao.2026.09.005_bib18","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-011226","article-title":"Onset and progression of atherosclerosis in patients with melanoma treated with immune checkpoint inhibitors","volume":"13","author":"van Dorst","year":"2025","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.jaccao.2026.09.005_bib19","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1038\/s41569-020-0352-5","article-title":"T cell subsets and functions in atherosclerosis","volume":"17","author":"Saigusa","year":"2020","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.jaccao.2026.09.005_bib20","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1161\/ATVBAHA.111.224709","article-title":"Impairment of the programmed cell death-1 pathway increases atherosclerotic lesion development and inflammation","volume":"31","author":"Bu","year":"2011","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jaccao.2026.09.005_bib21","doi-asserted-by":"crossref","first-page":"2974","DOI":"10.1172\/JCI31344","article-title":"Proatherogenic immune responses are regulated by the PD-1\/PD-L pathway in mice","volume":"117","author":"Gotsman","year":"2007","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jaccao.2026.09.005_bib22","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0093280","article-title":"Programmed cell death-1 deficiency exacerbates T cell activation and atherogenesis despite expansion of regulatory T cells in atherosclerosis-prone mice","volume":"9","author":"Cochain","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.jaccao.2026.09.005_bib23","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1161\/CIRCRESAHA.117.304611","article-title":"CD8+ T cells regulate monopoiesis and circulating Ly6C-high monocyte levels in atherosclerosis in mice","volume":"117","author":"Cochain","year":"2015","journal-title":"Circ Res"},{"key":"10.1016\/j.jaccao.2026.09.005_bib24","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1161\/ATVBAHA.115.306848","article-title":"Overexpression of cytotoxic T-lymphocyte-associated antigen-4 prevents atherosclerosis in mice","volume":"36","author":"Matsumoto","year":"2016","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jaccao.2026.09.005_bib25","doi-asserted-by":"crossref","DOI":"10.3390\/cells9091987","article-title":"Antibody-mediated inhibition of CTLA4 aggravates atherosclerotic plaque inflammation and progression in hyperlipidemic mice","volume":"9","author":"Poels","year":"2020","journal-title":"Cells"},{"key":"10.1016\/j.jaccao.2026.09.005_bib26","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1016\/j.ijcard.2012.12.085","article-title":"T-cell co-stimulation by CD28-CD80\/86 and its negative regulator CTLA-4 strongly influence accelerated atherosclerosis development","volume":"168","author":"Ewing","year":"2013","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.jaccao.2026.09.005_bib27","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2021.740531","article-title":"Stimulation of the PD-1 pathway decreases atherosclerotic lesion development in ldlr deficient mice","volume":"8","author":"Grievink","year":"2021","journal-title":"Front Cardiovasc Med"},{"key":"10.1016\/j.jaccao.2026.09.005_bib28","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1016\/j.jacbts.2023.12.007","article-title":"Costimulatory and coinhibitory immune checkpoints in atherosclerosis: therapeutic targets in atherosclerosis?","volume":"9","author":"Nitz","year":"2024","journal-title":"JACC Basic Transl Sci"},{"key":"10.1016\/j.jaccao.2026.09.005_bib29","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1093\/cvr\/cvac161","article-title":"Integrated single-cell analysis-based classification of vascular mononuclear phagocytes in mouse and human atherosclerosis","volume":"119","author":"Zernecke","year":"2023","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.jaccao.2026.09.005_bib30","doi-asserted-by":"crossref","first-page":"2396","DOI":"10.1161\/CIRCULATIONAHA.120.048708","article-title":"Immune checkpoint inhibitor therapy induces inflammatory activity in large arteries","volume":"142","author":"Calabretta","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.jaccao.2026.09.005_bib31","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCIMAGING.124.016851","article-title":"Longitudinal assessment of subclinical arterial inflammation in patients receiving immune checkpoint inhibitors by sequential [18F]FDG PET scans","volume":"18","author":"Bacmeister","year":"2025","journal-title":"Circ Cardiovasc Imaging"},{"key":"10.1016\/j.jaccao.2026.09.005_bib32","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1038\/s44161-025-00713-2","article-title":"Progenitor exhausted PD-1+ T cells are cellular targets of immune checkpoint inhibition in atherosclerosis","volume":"4","author":"Mulholland","year":"2025","journal-title":"Nat Cardiovasc Res"},{"key":"10.1016\/j.jaccao.2026.09.005_bib33","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1038\/s41591-019-0590-4","article-title":"Single-cell immune landscape of human atherosclerotic plaques","volume":"25","author":"Fernandez","year":"2019","journal-title":"Nat Med"},{"key":"10.1016\/j.jaccao.2026.09.005_bib34","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1161\/CIRCRESAHA.117.312513","article-title":"Atlas of the immune cell repertoire in mouse atherosclerosis defined by single-cell RNA-sequencing and mass cytometry","volume":"122","author":"Winkels","year":"2018","journal-title":"Circ Res"},{"key":"10.1016\/j.jaccao.2026.09.005_bib35","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1161\/CIRCRESAHA.120.316903","article-title":"Meta-analysis of leukocyte diversity in atherosclerotic mouse aortas","volume":"127","author":"Zernecke","year":"2020","journal-title":"Circ Res"},{"key":"10.1016\/j.jaccao.2026.09.005_bib36","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/s44161-022-00208-4","article-title":"Single-cell T cell receptor sequencing of paired human atherosclerotic plaques and blood reveals autoimmune-like features of expanded effector T cells","volume":"2","author":"Depuydt","year":"2023","journal-title":"Nat Cardiovasc Res"},{"key":"10.1016\/j.jaccao.2026.09.005_bib37","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.jaccao.2020.08.007","article-title":"Immune checkpoint inhibitor therapy aggravates T cell-driven plaque inflammation in atherosclerosis","volume":"2","author":"Poels","year":"2020","journal-title":"JACC CardioOncol"},{"key":"10.1016\/j.jaccao.2026.09.005_bib38","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/s00395-024-01068-8","article-title":"Molecular fingerprints of cardiovascular toxicities of immune checkpoint inhibitors","volume":"120","author":"Gergely","year":"2025","journal-title":"Basic Res Cardiol"},{"key":"10.1016\/j.jaccao.2026.09.005_bib39","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1056\/NEJMoa1707914","article-title":"Antiinflammatory therapy with canakinumab for atherosclerotic disease","volume":"377","author":"Ridker","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaccao.2026.09.005_bib40","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1038\/s44161-025-00640-2","article-title":"Preclinical mouse models of immune checkpoint inhibitor-associated myocarditis","volume":"4","author":"Fankhauser","year":"2025","journal-title":"Nat Cardiovasc Res"},{"key":"10.1016\/j.jaccao.2026.09.005_bib41","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1161\/CIRCULATIONAHA.121.056730","article-title":"Identification of pathogenic immune cell subsets associated with checkpoint inhibitor\u2013induced myocarditis","volume":"146","author":"Zhu","year":"2022","journal-title":"Circulation"},{"key":"10.1016\/j.jaccao.2026.09.005_bib42","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1093\/intimm\/dxq026","article-title":"PD-1 deficiency results in the development of fatal myocarditis in MRL mice","volume":"22","author":"Wang","year":"2010","journal-title":"Int Immunol"},{"key":"10.1016\/j.jaccao.2026.09.005_bib43","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/S1074-7613(00)80089-8","article-title":"Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor","volume":"11","author":"Nishimura","year":"1999","journal-title":"Immunity"},{"key":"10.1016\/j.jaccao.2026.09.005_bib44","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1126\/science.291.5502.319","article-title":"Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice","volume":"291","author":"Nishimura","year":"2001","journal-title":"Science"},{"key":"10.1016\/j.jaccao.2026.09.005_bib45","doi-asserted-by":"crossref","first-page":"2513","DOI":"10.4049\/jimmunol.181.4.2513","article-title":"Programmed death ligand 1 regulates a critical checkpoint for autoimmune myocarditis and pneumonitis in MRL mice","volume":"181","author":"Lucas","year":"2008","journal-title":"J Immunol"},{"key":"10.1016\/j.jaccao.2026.09.005_bib46","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abo1981","article-title":"Hormonal therapies up-regulate MANF and overcome female susceptibility to immune checkpoint inhibitor myocarditis","volume":"14","author":"Zhang","year":"2022","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.jaccao.2026.09.005_bib47","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/1074-7613(95)90125-6","article-title":"Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4","volume":"3","author":"Tivol","year":"1995","journal-title":"Immunity"},{"key":"10.1016\/j.jaccao.2026.09.005_bib48","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1158\/2159-8290.CD-20-0856","article-title":"A genetic mouse model recapitulates immune checkpoint inhibitor-associated myocarditis and supports a mechanism-based therapeutic intervention","volume":"11","author":"Wei","year":"2021","journal-title":"Cancer Discov"},{"key":"10.1016\/j.jaccao.2026.09.005_bib49","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1161\/CIRCULATIONAHA.122.062551","article-title":"Expansion of pathogenic cardiac macrophages in immune checkpoint inhibitor myocarditis","volume":"149","author":"Ma","year":"2024","journal-title":"Circulation"},{"key":"10.1016\/j.jaccao.2026.09.005_bib50","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1111\/bph.15984","article-title":"Characterization of immune checkpoint inhibitor-induced cardiotoxicity reveals interleukin-17A as a driver of cardiac dysfunction after anti-PD-1 treatment","volume":"180","author":"Gergely","year":"2023","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.jaccao.2026.09.005_bib51","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1093\/eurheartj\/ehab430","article-title":"Targeting early stages of cardiotoxicity from anti-PD1 immune checkpoint inhibitor therapy","volume":"43","author":"Michel","year":"2022","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jaccao.2026.09.005_bib52","doi-asserted-by":"crossref","first-page":"6640","DOI":"10.1038\/s41467-024-50996-5","article-title":"Gasdermin-E-mediated pyroptosis drives immune checkpoint inhibitor-associated myocarditis via cGAS-STING activation","volume":"15","author":"Sun","year":"2024","journal-title":"Nat Commun"},{"key":"10.1016\/j.jaccao.2026.09.005_bib53","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2022.111611","article-title":"Cardiac myosin-specific autoimmune T cells contribute to immune-checkpoint-inhibitor-associated myocarditis","volume":"41","author":"Won","year":"2022","journal-title":"Cell Rep"},{"key":"10.1016\/j.jaccao.2026.09.005_bib54","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.5858\/arpa.2019-0447-OA","article-title":"Histopathologic characterization of myocarditis associated with immune checkpoint inhibitor therapy","volume":"144","author":"Sobol","year":"2020","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/j.jaccao.2026.09.005_bib55","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.jaccao.2026.03.006","article-title":"Myocardial expression of PD-L1 as a marker of poor prognosis in immune checkpoint inhibitor-associated myocarditis","volume":"8","author":"Imaoka","year":"2026","journal-title":"JACC CardioOncol"},{"key":"10.1016\/j.jaccao.2026.09.005_bib56","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1038\/s41379-019-0363-0","article-title":"Immune checkpoint inhibitor associated myocarditis occurs in both high-grade and low-grade forms","volume":"33","author":"Champion","year":"2020","journal-title":"Mod Pathol"},{"key":"10.1016\/j.jaccao.2026.09.005_bib57","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.jaccao.2026.03.003","article-title":"PD-L1 in ICI myocarditis: when the immune brake fails","volume":"8","author":"Chen","year":"2026","journal-title":"JACC CardioOncol"},{"key":"10.1016\/j.jaccao.2026.09.005_bib58","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1002\/ejhf.2265","article-title":"Immune checkpoint inhibitor myocarditis: elucidating the spectrum of disease through endomyocardial biopsy","volume":"23","author":"Palaskas","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jaccao.2026.09.005_bib59","article-title":"PD-1\/PD-L1 signaling in non-ICI myocarditis","volume":"11","author":"Yousif","year":"2026","journal-title":"JACC Basic Transl Sci"},{"key":"10.1016\/j.jaccao.2026.09.005_bib60","doi-asserted-by":"crossref","first-page":"319","DOI":"10.4132\/jptm.2026.01.02","article-title":"Expression of PD-1\/PD-L1 pathway molecules in human cardiac allograft according to acute cellular rejection status: insights from a Korean Heart Transplant Cohort","volume":"60","author":"Yim","year":"2026","journal-title":"J Pathol Transl Med"},{"key":"10.1016\/j.jaccao.2026.09.005_bib61","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1038\/s41586-022-05432-3","article-title":"T cells specific for \u03b1-myosin drive immunotherapy-related myocarditis","volume":"611","author":"Axelrod","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.jaccao.2026.09.005_bib62","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/s41586-024-08105-5","article-title":"Immune responses in checkpoint myocarditis across heart, blood and tumour","volume":"636","author":"Blum","year":"2024","journal-title":"Nature"},{"key":"10.1016\/j.jaccao.2026.09.005_bib63","doi-asserted-by":"crossref","first-page":"5032","DOI":"10.1093\/eurheartj\/ehag371","article-title":"Immune checkpoint inhibitor myocarditis: a metagenomic investigation of infectious pathogens","volume":"47","author":"Lorca","year":"2026","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jaccao.2026.09.005_bib64","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1016\/j.jaccao.2023.09.004","article-title":"Severe vs nonsevere immune checkpoint inhibitor-induced myocarditis: contemporary 1-year outcomes","volume":"5","author":"Itzhaki Ben Zadok","year":"2023","journal-title":"JACC CardioOncol"},{"key":"10.1016\/j.jaccao.2026.09.005_bib65","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1186\/s40425-017-0296-4","article-title":"Smoldering myocarditis following immune checkpoint blockade","volume":"5","author":"Norwood","year":"2017","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.jaccao.2026.09.005_bib66","article-title":"Smoldering myocarditis unmasked by pembrolizumab-induced myositis: delayed-onset double M syndrome","volume":"30","author":"Mark","year":"2025","journal-title":"JACC Case Rep"},{"key":"10.1016\/j.jaccao.2026.09.005_bib67","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/S1471-4906(01)01976-7","article-title":"Post-translational protein modifications in antigen recognition and autoimmunity","volume":"22","author":"Doyle","year":"2001","journal-title":"Trends Immunol"},{"key":"10.1016\/j.jaccao.2026.09.005_bib68","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1002\/art.38637","article-title":"Citrulline-specific Th1 cells are increased in rheumatoid arthritis and their frequency is influenced by disease duration and therapy","volume":"66","author":"James","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.jaccao.2026.09.005_bib69","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1161\/CIRCULATIONAHA.120.051889","article-title":"Isolevuglandin-modified cardiac proteins drive CD4+ T-cell activation in the heart and promote cardiac dysfunction","volume":"143","author":"Ngwenyama","year":"2021","journal-title":"Circulation"},{"key":"10.1016\/j.jaccao.2026.09.005_bib70","doi-asserted-by":"crossref","first-page":"4585","DOI":"10.2147\/CMAR.S247554","article-title":"Multiple immune-related Adverse Events and anti-tumor efficacy: real-world data on various solid tumors","volume":"12","author":"Shimozaki","year":"2020","journal-title":"Cancer Manag Res"},{"key":"10.1016\/j.jaccao.2026.09.005_bib71","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1038\/s41698-025-01123-0","article-title":"A real-world cohort study of immune-related adverse events in patients receiving immune checkpoint inhibitors","volume":"9","author":"Wang","year":"2025","journal-title":"NPJ Precis Oncol"},{"key":"10.1016\/j.jaccao.2026.09.005_bib72","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1016\/S1470-2045(24)00278-X","article-title":"Multi-organ immune-related adverse events from immune checkpoint inhibitors and their downstream implications: a retrospective multicohort study","volume":"25","author":"Wan","year":"2024","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jaccao.2026.09.005_bib73","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1200\/JCO.2017.77.6385","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline","volume":"36","author":"Brahmer","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jaccao.2026.09.005_bib74","doi-asserted-by":"crossref","first-page":"4229","DOI":"10.1093\/eurheartj\/ehac244","article-title":"2022 ESC guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)","volume":"43","author":"Lyon","year":"2022","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jaccao.2026.09.005_bib75","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2026.14323","article-title":"Systemic glucocorticoid immunosuppression and survival among immune checkpoint inhibitor recipients","volume":"9","author":"Wan","year":"2026","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.jaccao.2026.09.005_bib76","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.cell.2016.08.069","article-title":"Loss of IFN-\u03b3 pathway genes in tumor cells as a mechanism of resistance to anti-CTLA-4 therapy","volume":"167","author":"Gao","year":"2016","journal-title":"Cell"},{"key":"10.1016\/j.jaccao.2026.09.005_bib77","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1158\/2159-8290.CD-22-1180","article-title":"Abatacept\/ruxolitinib and screening for concomitant respiratory muscle failure to mitigate fatality of immune-checkpoint inhibitor myocarditis","volume":"13","author":"Salem","year":"2023","journal-title":"Cancer Discov"},{"key":"10.1016\/j.jaccao.2026.09.005_bib78","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms14680","article-title":"T cell costimulation blockade blunts pressure overload-induced heart failure","volume":"8","author":"Kallikourdis","year":"2017","journal-title":"Nat Commun"},{"key":"10.1016\/j.jaccao.2026.09.005_bib79","doi-asserted-by":"crossref","DOI":"10.1126\/science.ade8520","article-title":"JAK inhibition enhances checkpoint blockade immunotherapy in patients with Hodgkin lymphoma","volume":"384","author":"Zak","year":"2024","journal-title":"Science"},{"key":"10.1016\/j.jaccao.2026.09.005_bib80","doi-asserted-by":"crossref","DOI":"10.1126\/science.adf1329","article-title":"Combined JAK inhibition and PD-1 immunotherapy for non-small cell lung cancer patients","volume":"384","author":"Mathew","year":"2024","journal-title":"Science"},{"key":"10.1016\/j.jaccao.2026.09.005_bib81","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1186\/s12885-015-1446-z","article-title":"Prognostic impact of CXCL16 and CXCR6 in non-small cell lung cancer: combined high CXCL16 expression in tumor stroma and cancer cells yields improved survival","volume":"15","author":"Hald","year":"2015","journal-title":"BMC Cancer"},{"key":"10.1016\/j.jaccao.2026.09.005_bib82","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001948","article-title":"CXCR6 deficiency impairs cancer vaccine efficacy and CD8+ resident memory T-cell recruitment in head and neck and lung tumors","volume":"9","author":"Karaki","year":"2021","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.jaccao.2026.09.005_bib83","article-title":"Pan-cancer mapping of single CD8+ T cell profiles reveals a TCF1:CXCR6 axis regulating CD28 co-stimulation and anti-tumor immunity","volume":"5","author":"Tooley","year":"2024","journal-title":"Cell Rep Med"},{"key":"10.1016\/j.jaccao.2026.09.005_bib84","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003100","article-title":"CXCR6 is required for antitumor efficacy of intratumoral CD8+ T cell","volume":"9","author":"Wang","year":"2021","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.jaccao.2026.09.005_bib85","doi-asserted-by":"crossref","first-page":"4512","DOI":"10.1016\/j.cell.2021.07.015","article-title":"CXCR6 positions cytotoxic T cells to receive critical survival signals in the tumor microenvironment","volume":"184","author":"Di Pilato","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.jaccao.2026.09.005_bib86","doi-asserted-by":"crossref","first-page":"3100","DOI":"10.1038\/s41591-023-02591-2","article-title":"Thymus alterations and susceptibility to immune checkpoint inhibitor myocarditis","volume":"29","author":"Fenioux","year":"2023","journal-title":"Nat Med"},{"key":"10.1016\/j.jaccao.2026.09.005_bib87","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1038\/nm955","article-title":"Autoantibodies against cardiac troponin I are responsible for dilated cardiomyopathy in PD-1-deficient mice","volume":"9","author":"Okazaki","year":"2003","journal-title":"Nat Med"},{"key":"10.1016\/j.jaccao.2026.09.005_bib88","doi-asserted-by":"crossref","DOI":"10.1126\/science.adz2742","article-title":"Pan-cancer spatial atlas of tertiary lymphoid structures","volume":"392","author":"Cho","year":"2026","journal-title":"Science"},{"key":"10.1016\/j.jaccao.2026.09.005_bib89","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1038\/s41571-022-00619-z","article-title":"B cells and tertiary lymphoid structures as determinants of tumour immune contexture and clinical outcome","volume":"19","author":"Fridman","year":"2022","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.jaccao.2026.09.005_bib90","doi-asserted-by":"crossref","DOI":"10.1126\/science.abf9419","article-title":"Tertiary lymphoid structures in cancer","volume":"375","author":"Schumacher","year":"2022","journal-title":"Science"},{"key":"10.1016\/j.jaccao.2026.09.005_bib91","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1093\/eurheartj\/ehaf315","article-title":"Immune checkpoint inhibitor-associated myocarditis: a novel risk score","volume":"47","author":"Power","year":"2026","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jaccao.2026.09.005_bib92","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-011404","article-title":"IL-1\u03b2 blockade prevents cardiotoxicity and improves the efficacy of immune checkpoint blockers and chemotherapy against pancreatic cancer in mice with obesity","volume":"13","author":"Talele","year":"2025","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.jaccao.2026.09.005_bib93","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1016\/S0140-6736(17)32247-X","article-title":"Effect of interleukin-1\u03b2 inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial","volume":"390","author":"Ridker","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.jaccao.2026.09.005_bib94","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1038\/s41577-022-00737-w","article-title":"Myeloid cell-targeted therapies for solid tumours","volume":"23","author":"Goswami","year":"2023","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.jaccao.2026.09.005_bib95","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2020.108571","article-title":"Distinct populations of immune-suppressive macrophages differentiate from monocytic myeloid-derived suppressor cells in cancer","volume":"33","author":"Kwak","year":"2020","journal-title":"Cell Rep"},{"key":"10.1016\/j.jaccao.2026.09.005_bib96","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1146\/annurev-immunol-020711-074950","article-title":"The dendritic cell lineage: ontogeny and function of dendritic cells and their subsets in the steady state and the inflamed setting","volume":"31","author":"Merad","year":"2013","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.jaccao.2026.09.005_bib97","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1001\/jamaoncol.2024.3065","article-title":"Immune checkpoint inhibitor-induced cardiotoxicity: a systematic review and meta-analysis","volume":"10","author":"Nielsen","year":"2024","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.jaccao.2026.09.005_bib98","article-title":"Fresh-blood immune profiling of immune-related adverse events in real-world patients identifies organ-specific and steroid responsiveness signatures","volume":"30","author":"Velasco Santiago","year":"2026","journal-title":"Immunooncol Technol"},{"key":"10.1016\/j.jaccao.2026.09.005_bib99","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2025-011590","article-title":"HLA-A\u221701:01-B\u221708:01-C\u221707:01 is linked to early-onset immune checkpoint inhibitor-induced myositis and myocarditis","volume":"13","author":"M\u00fcller-Jensen","year":"2025","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.jaccao.2026.09.005_bib100","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2025.1646231","article-title":"Clinical features and HLA typing of immune checkpoint inhibitor-associated myasthenia gravis, myocarditis and myositis","volume":"15","author":"Lin","year":"2025","journal-title":"Front Oncol"},{"key":"10.1016\/j.jaccao.2026.09.005_bib101","first-page":"84","article-title":"Clonal hematopoiesis of indeterminate potential is associated with increased risk of immune checkpoint inhibitor myocarditis in a prospective study of a cardio-oncology cohort","volume":"10","author":"Jaber Chehayeb","year":"2024","journal-title":"CardioOncology"},{"key":"10.1016\/j.jaccao.2026.09.005_bib102","doi-asserted-by":"crossref","first-page":"e940","DOI":"10.1161\/CIR.0000000000001404","article-title":"Clonal hematopoiesis and its cardiovascular implications: a scientific statement from the American Heart Association","volume":"153","author":"Rhee","year":"2026","journal-title":"Circulation"},{"key":"10.1016\/j.jaccao.2026.09.005_bib103","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2024.115186","article-title":"Optimized monitoring for immune checkpoint inhibitor induced myocarditis using high-sensitivity troponin-T","volume":"216","author":"Tomsitz","year":"2025","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.jaccao.2026.09.005_bib104","doi-asserted-by":"crossref","DOI":"10.1016\/j.jacadv.2024.101375","article-title":"Elevations of cardiac troponin in patients receiving immune checkpoint inhibitors: data from a prospective study","volume":"3","author":"van den Berg","year":"2024","journal-title":"JACC Adv"},{"key":"10.1016\/j.jaccao.2026.09.005_bib105","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1093\/eurheartj\/ehab674","article-title":"Defining cardiovascular toxicities of cancer therapies: an International Cardio-Oncology Society (IC-OS) consensus statement","volume":"43","author":"Herrmann","year":"2022","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jaccao.2026.09.005_bib106","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003594","article-title":"68Ga-DOTATOC PET\/CT to detect immune checkpoint inhibitor-related myocarditis","volume":"9","author":"Boughdad","year":"2021","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.jaccao.2026.09.005_bib107","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2021.614997","article-title":"Early detection of checkpoint inhibitor-associated myocarditis using 68Ga-FAPI PET\/CT","volume":"8","author":"Finke","year":"2021","journal-title":"Front Cardiovasc Med"},{"key":"10.1016\/j.jaccao.2026.09.005_bib108","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1007\/s11033-025-11095-w","article-title":"Cytokine profiling of patients with immune checkpoint inhibitor-associated myocarditis: a pilot study","volume":"52","author":"Li","year":"2025","journal-title":"Mol Biol Rep"},{"key":"10.1016\/j.jaccao.2026.09.005_bib109","doi-asserted-by":"crossref","first-page":"2014","DOI":"10.1056\/NEJMoa2003608","article-title":"A novel circulating microRNA for the detection of acute myocarditis","volume":"384","author":"Blanco-Dom\u00ednguez","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaccao.2026.09.005_bib110","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1016\/j.jaccao.2022.11.005","article-title":"Immune checkpoint inhibitor myocarditis treatment strategies and future directions","volume":"4","author":"Moslehi","year":"2022","journal-title":"JACC CardioOncol"},{"key":"10.1016\/j.jaccao.2026.09.005_bib111","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.1056\/NEJMc1901677","article-title":"Abatacept for severe immune checkpoint inhibitor-associated myocarditis","volume":"380","author":"Salem","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaccao.2026.09.005_bib112","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-004699","article-title":"Reversal of immune-checkpoint inhibitor fulminant myocarditis using personalized-dose-adjusted abatacept and ruxolitinib: proof of concept","volume":"10","author":"Nguyen","year":"2022","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.jaccao.2026.09.005_bib113","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1016\/j.immuni.2019.04.010","article-title":"Intratumoral activity of the CXCR3 chemokine system is required for the efficacy of anti-PD-1 therapy","volume":"50","author":"Chow","year":"2019","journal-title":"Immunity"},{"key":"10.1016\/j.jaccao.2026.09.005_bib114","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/j.jaccao.2022.09.005","article-title":"LAG3 regulates T cell activation and plaque infiltration in atherosclerotic mice","volume":"4","author":"Mulholland","year":"2022","journal-title":"JACC CardioOncol"}],"container-title":["JACC: CardioOncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666087326003078?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666087326003078?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T23:43:54Z","timestamp":1792712634000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666087326003078"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":114,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S2666087326003078"],"URL":"https:\/\/doi.org\/10.1016\/j.jaccao.2026.09.005","relation":{},"ISSN":["2666-0873"],"issn-type":[{"value":"2666-0873","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immune Responses in Checkpoint Inhibitor\u2013Associated Cardiovascular Immune\u2013Related Adverse Events","name":"articletitle","label":"Article Title"},{"value":"JACC: CardioOncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaccao.2026.09.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation.","name":"copyright","label":"Copyright"}]}}